Re: Response of a KIT-positive extra-abdominal fibromatosis to imatinib mesylate and KIT genetic analysis

J Natl Cancer Inst. 2006 Nov 1;98(21):1583-4. doi: 10.1093/jnci/djj417.
No abstract available

Publication types

  • Comment
  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Alanine
  • Antineoplastic Agents / therapeutic use*
  • Benzamides
  • Biomarkers, Tumor / genetics
  • Cysteine
  • Fibroma / drug therapy*
  • Fibroma / genetics
  • Humans
  • Imatinib Mesylate
  • Leucine
  • Methionine
  • Mutagenesis
  • Mutation*
  • Piperazines / therapeutic use*
  • Polymorphism, Genetic
  • Protein Kinase Inhibitors / therapeutic use*
  • Protein-Tyrosine Kinases / antagonists & inhibitors
  • Proto-Oncogene Proteins c-kit / genetics*
  • Pyrimidines / therapeutic use*
  • Treatment Outcome

Substances

  • Antineoplastic Agents
  • Benzamides
  • Biomarkers, Tumor
  • Piperazines
  • Protein Kinase Inhibitors
  • Pyrimidines
  • Imatinib Mesylate
  • Methionine
  • Protein-Tyrosine Kinases
  • Proto-Oncogene Proteins c-kit
  • Leucine
  • Cysteine
  • Alanine